SCHEMBL5367274

SCHEMBL5367274

COc1cccc(C=C2C(=O)Nc3c(Br)cc(Br)cc32)c1O

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MEN1 O00255 3/20 0.53
KMT2A Q03164 3/20 0.53
POLB P06746 1/20 0.53
GAA P10253 1/20 0.51
AR P10275 1/20 0.47
NPC1 O15118 2/20 0.46
RAF1 P04049 1/20 0.46
NTRK1 P04629 1/20 0.46
CCNA2 P20248 1/20 0.46
CDK2 P24941 1/20 0.46
CCNA1 P78396 1/20 0.46
RAB9A P51151 1/20 0.45
PLK4 O00444 2/20 0.44
PLK1 P53350 1/20 0.44
RET P07949 2/20 0.43
DHFR P00374 1/20 0.43
TLR2 O60603 1/20 0.43
ERN1 O75460 1/20 0.43
TLR1 Q15399 1/20 0.43
TLR6 Q9Y2C9 1/20 0.43

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7133980 0.89 NPC1 (0.60) MEN1KMT2ANPC1RAF1NTRK1
SCHEMBL7139919 0.88 IGF1R (0.52) MEN1KMT2APOLBGAAAR
SCHEMBL5366869 0.87 IGF1R (0.56) MEN1KMT2ARAF1NTRK1CCNA2
SCHEMBL7136300 0.85 MAP3K7 (0.45) MEN1KMT2APOLBRAF1NTRK1
SCHEMBL5366368 0.84 CDK2 (0.44) MEN1KMT2ANPC1RAF1NTRK1
SCHEMBL5365740 0.84 PTPN1 (0.51) NPC1RAF1NTRK1CCNA2CDK2
SCHEMBL5363581 0.83 ERN1 (0.48) RAF1NTRK1CCNA2CDK2CCNA1
SCHEMBL7134446 0.83 NPC1 (0.43) MEN1KMT2ANPC1RAF1PLK4
SCHEMBL7139577 0.81 MEN1 (0.50) MEN1KMT2APOLBGAAAR
SCHEMBL5366592 0.81 LRRK2 (0.48) POLBRAF1NTRK1CCNA2CDK2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7202265-B2 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. (US) 2007-04-10 US disclosed
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease SUGEN, INC. 2005-09-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050197382-A1 Indolinone combinatorial libraries and related products and methods for the treatment of disease FRK, PTK2, DSTYK MEN1 3855/4885KMT2A 4060/4885POLB 3294/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.